Korro Bio, Inc. (KRRO)

NCM – Real Time Price. Currency in USD

13.31

-0.01 (-0.08%)

Market open: Aug 12, 2026, 1:05 PM EDT

13.06

-0.26 (-1.95%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

10.08.2026

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

06.08.2026

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Ended second quarter 2026 with $137.9 million in cash, cash equivalents and marketable securities; provides sufficient resources to achieve value inflection points for multiple RNA editing programs including clinical data for KRRO-121 and KRRO-111; cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the second quarter ended June 30, 2026, and provided a corporate update.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Korro Bio, Inc. (KRRO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Korro Bio, Inc. (KRRO)

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

Korro Bio, Inc. (KRRO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Korro Bio, Inc. (KRRO)

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update